Provided herein are compounds of the formula (I): ##STR1##

as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.

 
Web www.patentalert.com

< Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1

< Inhibitors of glycogen synthase kinase 3

> Method for treating diseases associated with abnormal kinase activity

> Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof

~ 00262